BTBabak Tofighi

Babak Tofighi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Babak Tofighi has a total of 201 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Digital Psychosocial Interventions Tailored for People in Opioid Use Disorder Treatment: Scoping Review

    by Madison Scialanca, Karen Alexander, Babak Tofighi

    Background: A total of 60% of patients with opioid use disorder (OUD) leave treatment early. Psychosocial interventions can enhance treatment retention by addressing behavioral and mental health needs related to early treatment discontinuation, but intervention engagement is key. If well-designed, digital platforms can increase the engagement, reach, and accessibility of psychosocial interventions. Prior reviews of OUD treatment have predominantly focused on outcomes, such as reductions in substance use, without identifying the underlying behavior change principles that drive the effectiveness of interventions. Objective: This scoping review aims to document and describe recent digital psychosocial interventions, including their behavior change strategies, for patients receiving medication for OUD (MOUD). Methods: Predefined search terms were used to search Ovid, CINAHL, and PubMed databases for peer-reviewed literature published in the last 10 years. The database search resulted in 1381 relevant studies, and 16 of them remained after applying the inclusion criteria. Studies were included if they (1) evaluated a digital intervention with behavioral, psychosocial, or counseling components for people in OUD treatment and (2) were published in English in peer-reviewed journals. Results: The 16 studies reviewed comprised 6 randomized controlled trials, 6 pilot studies, 2 qualitative studies, and 2 retrospective cohort studies. Smartphone apps (n=8) were the most prevalent intervention delivery method, with other studies using telemedicine (n=3), virtual reality (n=1), telephone calls (n=1), or text messaging (n=3) to deliver psychosocial interventions in either a synchronous (n=7) or asynchronous (n=9) manner. The digital interventions reviewed predominately delivered cognitive behavioral therapy education through a phone call (n=1), a text message (n=2), a smartphone app (n=7), or tele-counseling (n=1). The predominant behavior change strategies implemented were self-monitoring, feedback and reinforcement, psychoeducation, cue awareness, and providing instruction. One intervention reviewed uses the evidence base of mindfulness-oriented recovery enhancement. Conclusions: Participants in the studies reviewed indicated a preference for digital, flexible, patient-centered psychosocial interventions that emphasized improved patient-provider relationships. While randomized controlled trials comprised a significant portion of the studies, the inclusion of pilot studies and qualitative research highlights the field’s ongoing exploration of feasibility and effectiveness. These findings underscore the growing role of digital health solutions in psychosocial care, though further research is needed to optimize engagement, delivery, and long-term outcomes.


  • Open Access

    Are Treatment Services Ready for the Use of Big Data Analytics and AI in Managing Opioid Use Disorder?

    by Matthew Amer, Rosalind Gittins, Antonio Martinez Millana, Florian Scheibein, Marica Ferri, Babak Tofighi, Frank Sullivan, Margaret Handley, Monty Ghosh, Alexander Baldacchino, et al.

    In this viewpoint, we explore the use of big data analytics and artificial intelligence (AI) and discuss important challenges to their ethical, effective, and equitable use within opioid use disorder (OUD) treatment settings. Applying our collective experiences as OUD policy and treatment experts, we discuss 8 key challenges that OUD treatment services must contend with to make the most of these rapidly evolving technologies: data and algorithmic transparency, clinical validation, new practitioner-technology interfaces, capturing data relevant to improving patient care, understanding and responding to algorithmic outputs, obtaining informed patient consent, navigating mistrust, and addressing digital exclusion and bias. Through this paper, we hope to critically engage clinicians and policy makers on important ethical considerations, clinical implications, and implementation challenges involved in big data analytics and AI deployment in OUD treatment settings.


  • Buprenorphine provider preferences to expanding harm reduction services in rural and suburban primary care settings: a short report

    by Babak Tofighi, Neelufar Sarah Franklin, Ethan Wolf, Helen Maria-Lekas, Crystal Fuller Lewis

    The opioid overdose crisis continues to worsen in suburban and rural regions. Expanding harm reduction approaches in primary care offers a patient-centered approach to reduce opioid overdoses. We conducted a semi-structured survey among 26 buprenorphine prescribers to assess acceptability of office-based harm reduction strategies for people who use opioids (PWUOs) and expanding partnerships with community stakeholders to ensure low-threshold access to buprenorphine. Respondents were mostly very or somewhat supportive of providing HIV testing (96.2%), information on opioid overdose prevention (100%), safe syringe disposal (100%) and use (100%), and referrals to free HIV testing (100%), social services (100%), naloxone sales in community pharmacies (96.2%) and partnering with pharmacists to facilitate referrals for patients requesting buprenorphine treatment (84.6%). Suggested strategies for enhancing care for PWUOs included addressing insurance-related barriers (e.g., prior authorization requirements, insufficient reimbursements), lifting of limits on patients prescribed buprenorphine, allowing for safe-injection sites, lifting urine drug testing requirements, integrating social services and mental health providers within primary care, and expanding the use of telebuprenorphine services. Findings from this study suggest strong buprenorphine provider support for adopting harm reduction strategies in primary care and collaborating with community pharmacists to facilitate referrals for PWUOs.

  • Open Access

    Digital Psychosocial Interventions Tailored for People with Opioid Use Disorder: Scoping Review (Preprint)

    by Madison Scialanca, Karen Alexander, Babak Tofighi

    BACKGROUND Sixty percent of patients with opioid use disorder (OUD) leave treatment early. Psychosocial interventions can enhance treatment retention by addressing behavioral and mental health needs related to early treatment discontinuation, but engagement is key. If well-designed, digital platforms can increase the engagement, reach, and accessibility of psychosocial interventions. OBJECTIVE This scoping review aims to document and describe recent digital psychosocial interventions for patients in medication-based OUD (MOUD) treatment. METHODS Predefined search terms were used to search Ovid, CINAHL, and PubMed databases for peer-reviewed literature published in the last ten years. The database search resulted in 1381 relevant articles, and 16 of them remained after applying the inclusion criteria. Studies were included if they: 1) evaluated a digital intervention with behavioral, psychosocial, or counseling components for people with OUD; and 2) were published in English in peer-reviewed journals. RESULTS The 16 articles reviewed comprised six randomized controlled trials, six pilot studies, two qualitative studies, and two retrospective cohort studies. Smartphone applications (n=8) were the most prevalent intervention delivery method, with other studies using telemedicine (n=3), virtual reality (n=1), telephone calls (n=1), or text messaging (n=3) to deliver psychosocial interventions in either a synchronous (n=7) or asynchronous (n=9) manner. The digital interventions reviewed predominately delivered cognitive behavioral therapy education and increased contact with providers. CONCLUSIONS Participants in the studies reviewed indicated a preference for digital, flexible, patient-centered psychosocial interventions that emphasized improved patient-provider relationships. Further studies are needed to establish an evidence base for digital psychosocial intervention efficacy through fully-powered randomized controlled trials to reduce early termination of OUD treatment.

  • Open Access

    Are Treatment Services Ready for the Use of Big Data Analytics and AI in Managing Opioid Use Disorder? (Preprint)

    by Matthew Amer, Rosalind Gittins, Antonio Martinez Millana, Florian Scheibein, Marica Ferri, Babak Tofighi, Frank Sullivan, Margaret Handley, Monty Ghosh, Alexander Baldacchino, et al.

    UNSTRUCTURED In this viewpoint, we explore the use of big data analytics and artificial intelligence (AI) and discuss important challenges to their ethical, effective, and equitable use within opioid use disorder (OUD) treatment settings. Applying our collective experiences as OUD policy and treatment experts, we discuss 8 key challenges that OUD treatment services must contend with to make the most of these rapidly evolving technologies: data and algorithmic transparency, clinical validation, new practitioner-technology interfaces, capturing data relevant to improving patient care, understanding and responding to algorithmic outputs, obtaining informed patient consent, navigating mistrust, and addressing digital exclusion and bias. Through this paper, we hope to critically engage clinicians and policy makers on important ethical considerations, clinical implications, and implementation challenges involved in big data analytics and AI deployment in OUD treatment settings.

  • Integrating Text Messaging in a Low Threshold Telebuprenorphine Program for New York City Residents with Opioid Use Disorder during COVID-19: A Pilot Randomized Controlled Trial

    by Babak Md Tofighi, Beita Bs Badiei, Ryan Badolato, Crystal Fuller Lewis, Edward Nunes, Anil Thomas, Joshua D. Md Lee

    Background: Pragmatic innovations are needed to optimize clinical outcomes among people who use opioids initiating buprenorphine. This pilot randomized controlled trial assessed the feasibility of integrating text messaging in a low threshold telebuprenorphine bridge program for people who use opioids during the COVID-19 pandemic. Methods: Eligible adult patients with opioid use disorder inducted on buprenorphine (N = 128) in the NYC Health+Hospitals Virtual Buprenorphine Clinic between May and November 2020 were randomized to an automated texting intervention based on the medical management model versus treatment as usual. A participant feedback survey was administered at 8 weeks (n = 18). Primary outcomes consisted of acceptability (eg, study enrollment, engagement with the intervention) and feasibility (eg, lack of phone number and/or mobile phone ownership) of integrating texting in clinical care. A secondary outcome included retention in treatment at week 8 (ie, active buprenorphine prescription within the prior 7 days). Results: Nearly all eligible patients consented to enroll in the study (90.8%) and few were excluded because of lack of mobile phone ownership (n = 27, 14.6%). Requests to discontinue receipt of texts (n = 6, 9.4%) was attributed to excessive message frequency, perceived lack of relevancy, and reduced interest in the intervention. Respondents completing the follow-up feedback survey were generally satisfied with the frequency of software-generated messages (14/18, 77.8%) and half shared text content with peers (9/18, 50%). There were no perceived issues with privacy, intrusiveness, or ease of use. Retention did not differ between participants randomized to the texting (M = 5.23 weeks, SD = 3.41) and treatment as usual groups (M = 4.98 weeks, SD = 3.34) at week 8 (P = 0.676). Conclusions: This pilot randomized controlled trial confirms high acceptability and feasibility of integrating an automated texting tool in a telebuprenorphine bridge program. Future studies should assess whether text messaging may be efficacious when combined with staff contact and content addressing social determinants of health.


  • Patient Perceptions of Integrating Meditation-based Interventions in Office-based Opioid Treatment with Buprenorphine: A Mixed-methods Survey

    by Babak Md Tofighi, Christina Marini, Joshua D. Md Lee, Eric L. Garland

    Introduction: Recent findings support the provision of meditation-based interventions (MBIs) in primary care. However, the acceptability of MBI among patients prescribed medications for opioid use disorder (eg, buprenorphine) in primary care remains unclear. This study assessed experiences and preferences for adopting MBI among patients prescribed buprenorphine in office-based opioid treatment (OBOT). Methods: This 23-item, semistructured cross-sectional survey was administered by study staff to patients enrolled in OBOT (N = 72) and consisted of demographic and clinical characteristics, perceptions, experiences with MBI, and preferred strategies to access MBI to support their treatment on buprenorphine. Results: Most participants reported practicing at least 1 category of MBI (90.3%) on at least a daily (39.6%) or weekly (41.7%) basis including (1) spiritual meditation (eg, centering prayer; 67.7%); (2) nonmantra meditation (eg, comfortable posture; 61.3%); (3) mindfulness meditation (eg, mindfulness-based stress reduction; 54.8%); and (4) mantra meditation (eg, transcendental meditation; 29.0%). Interest in MBI was motivated by improving one's general health and well-being (73.4%), treatment outcomes with medications for OUD (eg, buprenorphine; 60.9%), and relationships with others (60.9%). Perceived clinical benefits of MBI included reduced anxiety or depression symptoms (70.3%), pain (62.5%), illicit substance or alcohol use (60.9%), cravings for illicit substances (57.8%), and opioid-related withdrawal symptoms (51.6%). Conclusions: Findings from this study indicate high acceptability for adopting MBI among patients prescribed buprenorphine in OBOT. Further research is needed to assess the efficacy of MBI to improve clinical outcomes among patients initiating buprenorphine in OBOT.


  • Provider and administrator attitudes and experiences with implementing telebuprenorphine during the COVID-19 pandemic: a mixed-methods survey

    by Babak Tofighi, Rosalina Lopez, Gabriela Araujo, Joshua D. Lee, Elizabeth A. Samuels, Rachel S. Wightman, Jenna Butner

    This mixed-methods study assessed buprenorphine provider and administrator perceptions and experiences in offering telebuprenorphine during the COVID-19 pandemic.Semi-structured interviews were con...


  • Outcomes of a NYC Public Hospital System Low-Threshold Tele-Buprenorphine Bridge Clinic at 1 Year

    by Babak Tofighi, Jennifer McNeely, Jenny Yang, Anil Thomas, Daniel Schatz, Timothy Reed, Noa Krawczyk

    Background: This study evaluated clinical outcomes of a low barrier tele-buprenorphine bridge program for NYC residents with opioid use disorder (OUD) at 1 year during the coronavirus disease 2019 (COVID-19) pandemic. Methods and materials: This retrospective analysis of the NYC Health + Hospitals (NYC H + H) Virtual Buprenorphine Clinic registry assessed baseline demographic and clinical characteristics, rates of referrals to community treatment, and induction-related adverse events among city residents with OUD, from March 2020 to the end of March 2021. Results: The program enrolled 199 patients, of whom 62.3% were provided same-day visits (n = 124). Patients were enrolled in the program for a median of 14 days (range 0-130 days). Referrals sources included hospital and clinic staff (n = 83, 47.7%), word of mouth (n = 30, 17.2%), and correctional health or reentry services (n = 30, 17.2%). Induction-related adverse events were mostly limited to precipitated withdrawal symptoms (n = 21, 5%). Roughly half of patients were referred to community treatment (n = 109, 54.8%) and of those 51.4% (n = 56/109) completed at least one visit in community treatment. Discussion: Our experience indicates that a low threshold tele-buprenorphine bridge program in place of a safe and feasible approach to facilitating entry in community treatment for underserved people who use opioids in a large metropolitan area.


  • Open Access

    Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study

    by Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, et al.

    Background: Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-community treatment. Methods and findings: In-depth qualitative interviews were conducted among adult participants with opioid use disorder (OUD; n = 16) who were recently released from NYC jails and maintained on XRB after switching from daily sublingual buprenorphine (SLB). Interviews elaborated on the acceptability and barriers and facilitators of XRB treatment pre- and post-release. Interviews were audio recorded, transcribed, and analyzed for content related to factors influencing XRB treatment uptake and community reentry. Important themes were grouped into systems, medication, and patient-level factors. Key systems-level factors influencing initiation of XRB in jail included an alternative to perceived stigmatization and privacy concerns associated with daily in-jail SLB administration and less concerns with buprenorphine diversion. In-jail peer networks positively influenced participant adoption of XRB. XRB satisfaction was attributed to reduced in-jail clinic and medication administration visits, perceived efficacy and blockade effects upon the use of heroin/fentanyl following release, and averting the risk of criminal activities to fund opioid use. Barriers to retention included post-injection withdrawal symptoms and cravings attributed to perceived suboptimal medication dosing, injection site pain, and lack of in-jail provider information about the medication. Conclusion: Participants were generally favorable to XRB initiation in jail and retention post-release. Further studies are needed to address factors influencing access to XRB in criminal justice settings, including stigma, ensuring patient privacy following initiation on XRB, and patient-, provider-, and correctional staff education pertaining to XRB. Trial Registration ClinicalTrials.gov Identified: NCT03604159.